Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol with Sintilimab and Chemotherapy in Advanced NSCLC
NCT05979818Phase 1Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of propranolol in non-small cell lung cancer (NSCLC), sponsored by The Second Xiangya Hospital. Primary endpoints: Objective Response Rate at 2 years, Disease Control Rate at 2 years and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
propranolol
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05979818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979818.